HESTER

Press Release

22 July 2015

Q1 Results

Sales up by 5%, Net Profit up by 7%

India's leading animal healthcare company, Hester Biosciences Limited has reported the following Q1 FY15-16 results:

Financial Highlights

	Q1 FY15-16	Q1 FY14-15	Growth	FY14-15
Net Sales (in INR mil)	245.29	233.04	5%	900.37
Net Profit (in INR mil)	46.63	43.43	7%	145.82
EBITDA	33.34%	31.26%	7%	29.06%
EPS in INR	5.48	5.11	7%	17.14

- Sales and NP achieved in Q1FY15-16 are all time high.
- NP margin for Q1FY15-16 is 19.01% of sales as against 16.20% for FY14-15.
- Earnings per Share are at INR 5.48 for the quarter ended 30 June 2015 as compared to INR 5.11 for the quarter ended on 30 June 2014.

Company Performance

- The company got the manufacturing licence for 2 additional poultry vaccines:
  1. Salmonella Live vaccine
  2. IBH inactivated vaccine

  These 2 vaccines put together would contribute INR 20 million in this financial year
- Nepal plant is expected to go on stream in September 2015
- The company foresees a higher growth rate in the coming quarters in this financial year

For Hester Biosciences Limited

Rajiv Gandhi
CEO & Managing Director

HESTER BIOSCIENCES LIMITED

Pushpak, Level One, Panchvati Circle, Motilal Hirabhai Road, Ahmedabad, Gujarat 380006, India
Phone +91 79 2644 5107 Fax +91 79 2644 5105
Email mail@hester.in Web www.hester.in
CIN L99999GJ1987PLC022333